Merck Announces Upbeat Keytruda Data for Colorectal Cancer
Merck (MRK) reported positive preliminary results from its Phase 3 clinical trial of Keytruda. The trial KEYNOTE 177 is designed to evaluate the performance of the drug candidate as the first-line treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic colorectal cancer. The company reported that the study met one of its two primary endpoints while the second endpoint of overall survival is not yet mature.
The interim analysis carried out by an independent Data Monitoring Committee showed that Keytruda